Evidence map›Paper›PMID 26903362›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.

Harvey I Pass, Chandra Goparaju, Osvaldo Espin-Garcia, Jessica Donington, Michele Carbone, Devalben Patel, Zhuo Chen, Ronald Feld, John Cho, Shirish Gadgeel and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Guideline
  2. Pooled it
  3. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Harvey I PassLangone Medical Center, New York University, New York, New York. Electronic address: harvey.pass@med.nyu.edu.
Chandra GoparajuLangone Medical Center, New York University, New York, New York.
Osvaldo Espin-GarciaPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Jessica DoningtonLangone Medical Center, New York University, New York, New York.
Michele CarboneUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Devalben PatelPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Zhuo ChenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ronald FeldPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
John ChoPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Shirish GadgeelKarmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Antoinette WozniakKarmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Abraham ChachouaLangone Medical Center, New York University, New York, New York.
Natasha LeighlPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Ming-Sound TsaoPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Marc de PerrotPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Wei XuPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network and University of Toronto, Toronto, Ontario, Canada.

Funding

The North American Mesothelioma ConsortiumU01CA111295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUFLEJT, MARGARET ELISABETH, PASS, HARVEY IRA · 2005 to 2016
$4.8M
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA198138NCI NIH HHS U01 CA111295
6 · The paper itself

Abstract

objectivesPrognostic models for malignant pleural mesothelioma (MPM) are needed to prevent potentially futile outcomes. We combined MPM plasma biomarkers with validated clinical prognostic indices to determine whether stratification of risk for death in 194 patients with MPM improved.

methodsIndividuals were recruited from three different centers: a discovery cohort (83 patients with MPM) created by combining patients from two U.S. centers and a separate, independent cohort from Canada (111 patients with MPM). Univariable and multivariable analyses were performed on the initial discovery and independent cohorts separately. In the multivariable analyses, prognostic factors were adjusted for the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (PI) of mesothelioma. The prognostic significance of adding plasma biomarker data to the PI was determined by using the likelihood ratio test, comparing models with and without the addition of biomarker to the clinical PI. The predictive ability of the biomarker was then assessed formally using Harrell's C-index by applying the fitted model variables of the discovery cohort to the second, independent cohort, including and not including the biomarker with the PI.

resultsHigher levels of osteopontin and mesothelin were individually associated with worse prognosis after adjusting for the PI. In the independent cohort, incorporating either plasma osteopontin or mesothelin into the baseline predictive PI model substantively and statistically significantly improved Harrell's C-statistic. In the final prognostic model, log-osteopontin, EORTC clinical prognostic index, and hemoglobin remained as independently significant predictors and the entire prognostic model improved the optimism-corrected Harrell's C-index significantly, from 0.718 (0.67-0.77) to 0.801 (0.77-0.84).

conclusionsThese data suggest a possible role for preoperative plasma biomarkers to improve the prognostic capability of the EORTC PI of MPM.

Indexed as

AdultAgedAged, 80 and overBiomarkersCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedNeoplasm StagingPleural NeoplasmsPrognosisBiomarkersBiomarkersMesothelinMesotheliomaOsteopontinPrognosis

Identifiers

PMID26903362
PMCPMC5978729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.